Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q1 EPS of ($2.29), $0.46 worse than the analyst estimate of ($1.83). Revenue for the quarter came in at $0 versus the consensus estimate of $3.57 million.

Financial Guidance
Revolution Medicines is updating its full year 2026 GAAP operating expenses guidance to a range of $1.7 to $1.8 billion. The expected increase in 2026 GAAP operating expenses is due to higher projected non-cash stock-based compensation expense for full year 2026, now estimated to be between $260 and $280 million, as described earlier.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.